These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34602806)

  • 41. Discovery of a Potent HIV Integrase Inhibitor that Leads to a Prodrug with Significant anti-HIV Activity.
    Seo BI; Uchil VR; Okello M; Mishra S; Ma XH; Nishonov M; Shu Q; Chi G; Nair V
    ACS Med Chem Lett; 2011 Oct; 2(12):877-881. PubMed ID: 22328963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs.
    Krise JP; Charman WN; Charman SA; Stella VJ
    J Pharm Sci; 1999 Sep; 88(9):928-32. PubMed ID: 10479356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fostemsavir Tromethamine.
    Am J Health Syst Pharm; 2020 Nov; 77(23):1924-1927. PubMed ID: 32936234
    [No Abstract]   [Full Text] [Related]  

  • 44. Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
    Patel RV; Park SW
    Bioorg Med Chem; 2015 Sep; 23(17):5247-63. PubMed ID: 26116177
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phospholipid prodrug inhibitors of the HIV protease. Antiviral activity and pharmacokinetics in rats.
    Hostetler KY; Richman DD; Forssen EA; Selk L; Basava R; Gardner MF; Parker S; Basava C
    Biochem Pharmacol; 1994 Oct; 48(7):1399-404. PubMed ID: 7945439
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigational Antiretroviral Drugs: What is Coming Down the Pipeline.
    Gulick RM
    Top Antivir Med; 2018 Apr; 25(4):127-132. PubMed ID: 29689540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay.
    Gunaseelan S; Debrah O; Wan L; Leibowitz MJ; Rabson AB; Stein S; Sinko PJ
    Bioconjug Chem; 2004; 15(6):1322-33. PubMed ID: 15546199
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Small molecule HIV entry inhibitors: Part II. Attachment and fusion inhibitors: 2004-2010.
    Singh IP; Chauthe SK
    Expert Opin Ther Pat; 2011 Mar; 21(3):399-416. PubMed ID: 21342055
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
    Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibitors of HIV-1 attachment. Part 11: the discovery and structure-activity relationships associated with 4,6-diazaindole cores.
    Bender JA; Yang Z; Eggers B; Gong YF; Lin PF; Parker DD; Rahematpura S; Zheng M; Meanwell NA; Kadow JF
    Bioorg Med Chem Lett; 2013 Jan; 23(1):218-22. PubMed ID: 23206859
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs.
    Krise JP; Narisawa S; Stella VJ
    J Pharm Sci; 1999 Sep; 88(9):922-7. PubMed ID: 10479355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV.
    O'Dowd H; Shannon DE; Chandupatla KR; Dixit V; Engtrakul JJ; Ye Z; Jones SM; O'Brien CF; Nicolau DP; Tessier PR; Crandon JL; Song B; Macikenas D; Hanzelka BL; Le Tiran A; Bennani YL; Charifson PS; Grillot AL
    ACS Med Chem Lett; 2015 Jul; 6(7):822-6. PubMed ID: 26191374
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
    Landry I; Zhu L; Abu Tarif M; Hruska M; Sadler BM; Pitsiu M; Joshi S; Hanna GJ; Lataillade M; Boulton DW; Bertz RJ
    Antimicrob Agents Chemother; 2016 May; 60(5):2782-9. PubMed ID: 26902761
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond.
    Cihlar T
    Curr Opin HIV AIDS; 2006 Sep; 1(5):373-9. PubMed ID: 19372836
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery and optimization of 2-pyridinone aminal integrase strand transfer inhibitors for the treatment of HIV.
    Schreier JD; Embrey MW; Raheem IT; Barbe G; Campeau LC; Dubost D; McCabe Dunn J; Grobler J; Hartingh TJ; Hazuda DJ; Klein D; Miller MD; Moore KP; Nguyen N; Pajkovic N; Powell DA; Rada V; Sanders JM; Sisko J; Steele TG; Wai J; Walji A; Xu M; Coleman PJ
    Bioorg Med Chem Lett; 2017 May; 27(9):2038-2046. PubMed ID: 28285916
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges.
    Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2011 Jun; 36(2):49-59. PubMed ID: 21404122
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel Antiretroviral Agents.
    Cambou MC; Landovitz RJ
    Curr HIV/AIDS Rep; 2020 Apr; 17(2):118-124. PubMed ID: 32052271
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug.
    Brown J; Chien C; Timmins P; Dennis A; Doll W; Sandefer E; Page R; Nettles RE; Zhu L; Grasela D
    J Pharm Sci; 2013 Jun; 102(6):1742-1751. PubMed ID: 23681563
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists.
    Jana S; Mandlekar S; Marathe P
    Curr Med Chem; 2010; 17(32):3874-908. PubMed ID: 20858214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes.
    Xu H; Majmudar JD; Davda D; Ghanakota P; Kim KH; Carlson HA; Showalter HD; Martin BR; Amidon GL
    Mol Pharm; 2015 Sep; 12(9):3399-407. PubMed ID: 26262434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.